Our research revealed that everolimus reversed the promoting effects of WSB2 overexpression on hepatocellular carcinogenesis in vitro and in vivo, which indicated that HCC patients with high WSB2 expression may benefit from everolimus treatment. Here, WSB2 is linked to hepatocellular carcinoma.